# A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

> **NCT07635524** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hoag Memorial Hospital Presbyterian** · enrollment: 34 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Cu-NU101

## Key facts

- **NCT ID:** NCT07635524
- **Lead sponsor:** Hoag Memorial Hospital Presbyterian
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635524, "A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07635524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*